Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, Chung DJ, Doddi S, Falchi L, Gyurkocza B, Hamilton A, Lin YH, Jakubowski AA, Joffe E, Landau HL, Lin RJ, Mailankody S, Palomba ML, Park JH, Perales MA, Ponce DM, Ramanathan LV, Salles GA, Scordo M, Seo SK, Shah UA, Stein EM, Straus D, Usmani SZ, Young JW, Zelenetz AD, Noy A, Vardhana SA.
Stuver R, et al. Among authors: jakubowski aa.
Cancer Cell. 2022 Jun 13;40(6):590-591. doi: 10.1016/j.ccell.2022.05.007. Epub 2022 May 16.
Cancer Cell. 2022.
PMID: 35598602
Free PMC article.
No abstract available.